ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more
ABIVAX Société Anonyme (AAVXF) - Total Liabilities
Latest total liabilities as of September 2025: $140.81 Million USD
Based on the latest financial reports, ABIVAX Société Anonyme (AAVXF) has total liabilities worth $140.81 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ABIVAX Société Anonyme - Total Liabilities Trend (2013–2024)
This chart illustrates how ABIVAX Société Anonyme's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ABIVAX Société Anonyme Competitors by Total Liabilities
The table below lists competitors of ABIVAX Société Anonyme ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Comens New Materials
SHE:300200
|
China | CN¥767.80 Million |
|
Custom Truck One Source Inc
NYSE:CTOS
|
USA | $2.76 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥694.43 Million |
|
Suntront Tech
SHE:300259
|
China | CN¥502.55 Million |
|
Myson Century, Inc.
TWO:5314
|
Taiwan | NT$553.41 Million |
|
SEALSQ Corp
NASDAQ:LAES
|
USA | $23.89 Million |
|
Longkou Union Chemical Co. Ltd. A
SHE:301209
|
China | CN¥205.12 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down ABIVAX Société Anonyme's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ABIVAX Société Anonyme's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ABIVAX Société Anonyme (2013–2024)
The table below shows the annual total liabilities of ABIVAX Société Anonyme from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $164.64 Million | +25.63% |
| 2023-12-31 | $131.05 Million | +83.37% |
| 2022-12-31 | $71.47 Million | -12.40% |
| 2021-12-31 | $81.59 Million | +22.46% |
| 2020-12-31 | $66.62 Million | +66.78% |
| 2019-12-31 | $39.95 Million | +105.98% |
| 2018-12-31 | $19.39 Million | +244.17% |
| 2017-12-31 | $5.63 Million | +45.23% |
| 2016-12-31 | $3.88 Million | -14.35% |
| 2015-12-31 | $4.53 Million | +12.38% |
| 2014-12-31 | $4.03 Million | -9.29% |
| 2013-12-31 | $4.44 Million | -- |